How is ARA-290 (Cibinetide) administered?
This describes how ARA-290 (Cibinetide) is typically administered in clinical and research references, not a self-administration guide. The usual route is Subcutaneous, on a once daily schedule, generally over 4-12 weeks. Specific dosing is individual and beyond general information, and human evidence for ARA-290 (Cibinetide) is limited.
Administration at a glance (reference data)
- Route: Subcutaneous
- Schedule: Once daily
- Cycle length: 4-12 weeks
- Half-life: ~20 min terminal (subcutaneous; ~2 min IV)
References
- ARA-290 (cibinetide) in sarcoidosis-associated small fiber neuropathy — Heij L et al., Mol Med, 2012
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density — Dahan A, Dunne A, Swartjes M, et al. (Brines M, senior author) — Molecular Medicine, 2013
- ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes — Brines M, Dunne AN, van Velzen M, et al. — Molecular Medicine, 2015
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on ARA-290 (Cibinetide)
Full ARA-290 (Cibinetide) breakdownARA-290 (Cibinetide) what it's used forARA-290 (Cibinetide) side effectsARA-290 (Cibinetide) mistakes to avoidARA-290 (Cibinetide) who should avoid itARA-290 (Cibinetide) half-lifeARA-290 (Cibinetide) how long to workARA-290 (Cibinetide) legal statusARA-290 (Cibinetide) how it worksAsk the AI Coach
Last updated 2026-06-15.